Schindler Florian, Schinkoethe Timo, Mahner Sven, Kolben Thomas, Wuerstlein Rachel, Culmsee Carsten, Harbeck Nadia, Eggersmann Tanja K
Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany.
CANKADO, Kirchheim, Germany.
Ther Adv Drug Saf. 2023 Aug 24;14:20420986231188845. doi: 10.1177/20420986231188845. eCollection 2023.
Modern oral antineoplastic and immune-modulating drugs offer an array of therapeutic advantages, and yet pose challenges in daily use for patients, physicians and pharmacists. In contrast to intravenous administration, these drugs are not subject to direct medical control. Recently, we have seen a huge rise in sales of non-prescription over-the-counter (OTC) medicines the internet without any advice from a healthcare professional.
The aim of this study was to investigate whether the risk of known potential drug-drug interactions between modern oral antineoplastic and immune-modulating drugs and OTC drugs differs between sales in traditional community pharmacies online pharmacies.
Real-life sales data from community and online pharmacies were used as basis for the analysis.
We determined the most frequently purchased antineoplastic and immune-modulating drug-substances in 14 local community pharmacies within the Munich area, Germany and identified the OTC substance groups that could potentially cause interactions with oncological therapies. Using sales data from 11 local community pharmacies and three online pharmacies, we investigated whether OTC purchases differed between the two sales channels.
We identified 10 relevant OTC substance classes and detected significant variations in patients' preferred sales channels between the drug classes. Certain OTC drugs, which seem to be bought more often over the internet, pose risks during antineoplastic and immune-modulating therapy.
Patients should therefore be proactively made aware of the corresponding risks in order not to jeopardize the activity of the antineoplastic and immune-modulating drugs and thus the success of their therapy.
现代口服抗肿瘤和免疫调节药物具有一系列治疗优势,但在患者、医生和药剂师的日常使用中也带来了挑战。与静脉给药不同,这些药物不受直接医疗控制。最近,我们发现非处方非处方药(OTC)在没有医疗保健专业人员建议的情况下通过互联网的销售额大幅上升。
本研究的目的是调查现代口服抗肿瘤和免疫调节药物与非处方药之间已知潜在药物相互作用的风险在传统社区药店和在线药店的销售中是否存在差异。
将社区和在线药店的实际销售数据用作分析基础。
我们确定了德国慕尼黑地区14家当地社区药店中最常购买的抗肿瘤和免疫调节药物物质,并确定了可能与肿瘤治疗产生相互作用的非处方物质类别。利用11家当地社区药店和3家在线药店的销售数据,我们调查了两种销售渠道的非处方药品购买情况是否存在差异。
我们确定了10种相关的非处方物质类别,并发现不同药物类别之间患者偏好的销售渠道存在显著差异。某些似乎在互联网上更常被购买的非处方药,在抗肿瘤和免疫调节治疗期间存在风险。
因此,应积极让患者了解相应风险,以免危及抗肿瘤和免疫调节药物的活性,从而影响治疗效果。